Radiofrequency-assisted Liver Resection in Intractable Liver Cancer

NCT04413526 | Completed

• 1 other identifier: radiofrequency liver resection
• Study Type: observational
• Target: 199
• Locations: 1 country
• Sites: 1

Brief Summary

In this retrospective study, the investigators assessed the application of radiofrequency-assisted liver resection in intractable liver cancer resection, and plan to analysis the different factors.

Conditions

Liver Cancer

Keywords

RFA; liver cancer; surgical resection

Outcome Measures

Primary Outcomes (1)

• The survival rates for one-year to five-year

  The survival rates was defined as the percentage of liver cancer for five years.

  5 years

Secondary Outcomes (2)

• The hospital stay

  3 months

• The Child-Pugh score after therapy

  3 months

Study Arms (3)

radiofrequency-assisted liver resection

radiofrequency-assisted liver resection for intractable liver cancer

Procedure: radiofrequency

TACE(transcatheter arterial chemoembolization)

temporary TACE for intractable liver cancer

Procedure: TACE

radiofrequency ablation plus TACE

radiofrequency ablation plus TACE for intractable liver cancer

Procedure: TACE+radiofrequency

Interventions

radiofrequency PROCEDURE

radiofrequency combined with liver resection

radiofrequency-assisted liver resection

TACE PROCEDURE

only TACE treatment

TACE(transcatheter arterial chemoembolization)

TACE+radiofrequency PROCEDURE

TACE followed by radiofrequency

radiofrequency ablation plus TACE

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

HCC patients

You may qualify if:

• Ultrasound-guided fine-needle aspiration pathology or postoperative pathology was confirmed to be liver cancer, no pathological results according to China 's 2017 version of the hepatocarcinoma (HCC) diagnosis and treatment specifications, in line with the standard clinical diagnosis of liver cancer
• According to Barcelona Clinic Liver Cancer (BCLC) staging criteria, it is stage C (stage C: single tumour\> 5 cm or more than three tumours, and at least one tumour\> 3 cm, liver function Child-Pugh A or B, with lymph node metastasis or distant metastasis or portal vein or Venous liver trunk is invaded, penance Status (PST) score 1-2 points)

You may not qualify if:

• HCC patients with other malignant tumours
• Metastatic liver tumour
• Patients with liver abscess
• Patients with organ dysfunction

Sponsors & Collaborators

• Hepatopancreatobiliary Surgery Institute of Gansu Province: lead

Study Sites (1)

Hepatopancreatobiliary Surgery Institute of Gansu Province

Lanzhou, Gansu, 730000, China

Location

Related Publications (1)

• Sun Y, Ji S, Ji H, Liu L, Li C. Clinical efficacy analysis of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in primary liver cancer and recurrent liver cancer. J BUON. 2019 Jul-Aug;24(4):1402-1407.

  PMID: 31646783 BACKGROUND

MeSH Terms

Conditions

Liver Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Liver Diseases

Study Officials

• Wenbo Meng, M.D., Ph. D.

  Hepatopancreatobiliary Surgery Institute of Gansu Province

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: head of surgery

Study Record Dates

• First Submitted: May 25, 2020
• First Posted: June 4, 2020
• Study Start: May 25, 2020
• Primary Completion: November 18, 2021
• Study Completion: November 18, 2021
• Last Updated: November 19, 2021

Record last verified: 2021-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)